In vitro activity of telithromycin against Gram-negative bacterial pathogens - 16/08/11
Summary |
Objectives |
To investigate the in vitro activity of the ketolide anti-bacterial telithromycin against a range of commensal bacteria and common aerobic Gram-negative respiratory and non-respiratory pathogens.
Methods |
Isolates were derived from both clinical material supplied by centres in various European countries and patients with community-acquired respiratory tract infections (RTIs) from centres worldwide as part of a longitudinal surveillance study. Telithromycin susceptibility testing was conducted using methods in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted using CLSI breakpoints.
Results |
Telithromycin displayed the highest activity against clinical isolates of Haemophilus spp., Neisseria spp., Bordetella pertussis, Legionella pneumophila and Moraxella catarrhalis, with low activity against a number of other bacterial species, including Acinetobacter spp., Enterobacteriaceae spp., Vibrio spp., Campylobacter jejuni, Aeromonas hydrophila, Plesiomonas shigelloides and Pseudomonas aeruginosa.
Conclusions |
Telithromycin provides coverage of key Gram-negative respiratory tract pathogens, but has minimal activity against Gram-negative non-respiratory pathogens and commensal bacteria. These data support the use of telithromycin as an alternative empirical therapy for community-acquired RTIs.
Le texte complet de cet article est disponible en PDF.Keywords : Telithromycin, Non-respiratory bacterial pathogens
Plan
Vol 52 - N° 3
P. 178-180 - mars 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?